G1 Therapeutics (GTHX)
(Real Time Quote from BATS)
$3.00 USD
-0.21 (-6.54%)
Updated Jun 6, 2024 02:12 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Brokerage Reports
0 items in cart
G1 Therapeutics [GTHX]
Reports for Purchase
Showing records 61 - 80 ( 351 total )
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
3Q22: Q3 COSELA Revenue Flat. Estimates Reduced. PT to $34.
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
3Q22 Results; Lower Than Expected Cosela Sales; Lowering Price Target to $57
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Investigator-Initiated Study of Cosela and Zepzelca in ES-SCLC Patients Announced
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Complete Enrollment Achieved in Preserve 2 Trial of Cosela in Metastatic TNBC
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Trilaciclib Cycling Towards a Trifecta of Data Next Quarter
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Cosela (trilaciclib) Research and Development Day
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
2Q22 Results; Cosela Sales Exceed Our Expectations; Clinical Trial Data From Five Studies Over the Next 18 Months
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
2Q22: Sequential COSELA Revenue Growth Continues with In-House Sales-$35PT
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T